Small-molecule irreversible tyrosine kinase inhibitors as high potent agents have led to improvements in disease-free and overall survival in patients with HER2-amplified cancer. The approved ...

A novel inhibitor-loaded bilayer hybrid system based on the LDH inner layer and MOF outer layer is designed on an aluminum alloy 2A12 surface to improve corrosion performance. The hybrid film system ...

Including PD-L1 inhibitors, this category had estimated sales of $48.7 billion in 2024. 5 Some analysts believe that figure could triple in the next decade. 5,6 ...

Afimetoran (BMS 986256) is a potent, selective, and orally bioavailable inhibitor of TLR7/8 currently in clinical development for immune mediated diseases. Previously, we observed that afimetoran ...

Panelists discuss potential changes to clinical pathways for Bruton tyrosine kinase (BTK) inhibitor therapies as a result of the Inflation Reduction Act (IRA), focusing on how shifting costs and ...

The Food and Drug Administration (FDA) has received Fast Track designation for FNP-223 for the treatment of progressive supranuclear palsy (PSP). FNP-223, previously known as ASN90, is a ...

Next, experts said, discussions will focus on other decisions, such as when and whether to prescribe the SGLT2 inhibitors with GLP-1 receptor agonists for the best outcomes. The Path From Glucose ...

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...

197. Arangalage D, Degrauwe N, Michielin O, Monney P, Özdemir BC. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.

- Results will be presented at the American Cough Conference on June 7, 2025 - NHP receptor occupancy studies indicate increasing the dose in Phase 2 from 20 mg to 40-80 mg is likely to significantly ...